展示10.4

註冊權協議

本登記權協議 （本「協議 ”), 於2025年[•]日生效，由GlycoMimetics, Inc.，一間特拉華州公司（以下簡稱為“權益代理 ”），以及簽署本協議的幾位投資者（各自為“投資者”和他們各自的被允許轉讓方，合稱為“投資者”). 在此使用的大寫術語，且在此未另有定義的，應具有證券購買協議中公司和投資者方所訂的相應含義，該協議日期為2024年10月28日（根據情況修訂、重述、補充或以其他方式修改，統稱為“購買協議”).

鑑於：

A.            根據購買協議的條款和條件，公司已同意向某些投資者發行，並且這些投資者已同意分別且非共同地購買，總金額達$[•]的(x)股份（即“股票”），和/或(y)預付權證（即“權證”），以購買普通股票，每項根據購買協議。 初始股份和預付測得授權行使的普通股票股份，這裡統稱為“該”初始股份公司普通股每股價值$0.001的股價（“”）和/或預付權證（“”普通股”）和（y）預付權證進行購股的擔保條件，視情況而定。初始股票及預付測向發行普通股的股份可本定為“該”預購權證”）股份.”

B.             為了誘使投資者進入購買協議，公司已同意根據1933年美國證券法（經修訂）及其相關規則和規定，或任何類似的後續法令（總稱為「證券法」，以及適用的州證券法。

因此，根据本协议中包含的相互承诺，各方同意将上述背景资料纳入本协议，并且各方在其他方面如下达成协议: 鑑於本協議中包含的承諾和雙方所訂立的協定以及其他充分而有價值的考慮，公司和投資者在此確認已收到並承認足夠的對價，特此同意如下：

根據本協議的目的，以下術語應具有以下含義：

(a)            “申報 期限”表示，就本協議所要求的首次註冊聲明而言，距離結束日期後的第30個日曆日，並且關於此處提交的任何新註冊聲明或其他註冊聲明，距離(一) 公司被SEC指南允許提交有關可註冊證券的新註冊聲明的日期和(二) 公司意識到需要提交有關可註冊證券的新註冊聲明之日後的第30個日曆日。

(b)            “Person「」表示任何個人或實體，包括但不限於任何公司、有限責任公司、協會、合夥組織、組織、業務、個人、政府或政治轄區或政府機構。

(c)            “註冊,” “已登記,登記「指根據《證券法》的規定，準備並提交公司的一個或多個註冊申報書，並提供持續發行證券的安排，以及美國證券交易委員會對該註冊聲明或生效的宣布或命令（即「美國證券交易委員會”).

(d)            “可註冊證券「股份」指（i）對股份，（ii）根據約定的某種合併與重組計劃，該計劃約定的日期前後向投資者發行的任何普通股股份，在此日期前後，由公司、新月生物醫藥公司、Gemini合併子公司和Gemini合併子公司II，有條件發行或可能發行的（iii）因任何股票分拆、細分、股票股利、資本重組、換股或類似事件而對前述股份發行或可發行的普通股。無可註冊證券在最早的以下情況之一發生後不再被視爲可註冊證券（公司不需要保持任何有效性，或在此之下就該等情況提出另一份註冊聲明）：（A）此類投資者已再售所涵蓋於註冊聲明下的可註冊證券的日期；（B）此類可註冊證券已依照第144條規則由此類投資者以前售出；（C）此類證券在不受第144條規則中的成交額或銷售方式限制的情況下，對此類投資者有資格再次出售，並且不要求公司遵守第144條規則下的當前公共信息要求；（D）自本協議日期後五（5）年。

(e)            “註冊 費用「費用」表示公司爲根據本協議進行的任何註冊而發生的所有註冊和備案費用，包括（i）所有註冊、資格和備案費用、印刷費用以及與向SEC、FINRA或任何其他監管機構進行的備案有關的任何其他費用和開支、（ii）所有與遵守或爲了根據任何證券或「藍天」法律出售可登記證券而進行的費用和開支、（iii）所有印刷、複製、文字處理、傳呼、電話、傳真和交付費用，以及（iv）公司的律師費和所有公司獨立註冊會計師的費用和支出（包括任何特別審計和出具相信函所需的費用）；但公司絕不對任何投資者的承銷、經紀或類似費用或佣金，或投資者在《購買協議》中未另行規定的任何法律費用或其他費用負責。

(f)            “註冊聲明書「註冊聲明」 指公司根據《證券法》向SEC註冊或擬向SEC註冊的任何註冊聲明， 其中包括註冊可登記證券的相關初稿或最終招股說明書、修改和補充資料；前後生效修正案；以及註冊聲明中通過參考併入文中以符合適用證券法律而必要的所有展品和所有材料。"註冊聲明" 還包括一個新的註冊聲明，在其各自生效時進行的修改，包括作爲其一部分提交的所有文件或通過引用納入其中的文件，以及包括隨後提交給SEC的招股說明書中包含的任何信息。

(g)            “SEC 指導「」表示（i）任何SEC工作人員公開發布的書面或口頭指導，或SEC工作人員的任何評論、要求或要求（無論是否公開），但前提是SEC將任何此類口頭指導、評論、要求轉書面形式（如果未公開，應在投資者要求下與投資者分享），以及（ii）《證券法》。

(h)            “銷售費用「」指適用於可登記證券銷售的所有承銷折扣和銷售佣金，以及與投資者處置其可登記證券相關的所有類似費用和佣金。

(a)            必須 註冊公司應在合理可行的最短時間內，但絕不遲於提交期限，準備並向SEC備案一份首次註冊聲明（即“初始註冊聲明”），以覆蓋所有可登記證券的轉讓。在提交註冊聲明之前，公司應向投資者提供一份註冊聲明副本。在提交註冊聲明之前，投資者及其各自的律師應至少有三（3）個工作日的時間來審閱並對該註冊聲明及對該註冊聲明的任何修訂或補充以及相關招股說明書（其中包括任何被其引用的文件）提出意見。公司應（a）誠實考慮投資者或其律師合理提出的任何評論，並在該文件在向SEC提交前的文件，和（b）不在任何向投資者的信息的註冊聲明或相關招股說明書或任何修訂或補充文件中包含欺詐陳述或未能載明必須在其中載明的事實或在其表述的輕視情況下使其表述在其製作時不具有誤導性，除非（在公司意見下）該信息根據任何適用法律或法規或SEC指引要求。每位投資者應在本協議中提到的任何登記註冊事項中合理要求的情況下向公司提供有關該投資者的所有信息。

(b)            有效性公司應盡商業上的合理努力，使初始註冊聲明及任何修正在最早可能日期被美國證券交易委員會宣佈生效，但不遲於初始申報日期後的第六十（60）個日曆日，如果美國證券交易委員會通知公司將「審查」初始註冊聲明，並在公司被美國證券交易委員會口頭或書面通知（以較早者爲準）的第五（5）個工作日之後確定該初始註冊聲明將不會「審核」或不會再受到進一步審查時（稱爲“有效性 截止日期”），公司應儘快通過電子郵件通知投資者，並在初始註冊聲明生效或補充後的二十四（24）小時內提供任何相關擬用於出售或處置與之相關的證券的招股說明書副本。公司應盡商業上的合理努力，根據證券法發佈的第415條規定，使初始註冊聲明持續有效，並隨時供投資者轉售其中涵蓋的所有可登記證券，直至以下事件中較早的發生日期：（i）投資者應已轉售其中涵蓋的所有可登記證券的日期；（ii）投資者可以根據第144條規定在無需註冊的情況下轉售可登記證券，並且不受任何成交量或銷售方式限制的限制，並無需公司符合證券法第144條下的當前公衆信息要求或任何類似規定的要求，以及（iii）本協議簽訂日期後五（5）年後的日期（註冊期”）。初始註冊聲明（包括任何修正或補充及其中包含的招股說明書）不得包含任何重大事實的不實陳述或遺漏必須在其中陳述的重大事實，或在作出陳述時的情況下，未能使其，不違反法規。

(c)            註冊股票數量充分在任何時間，初次註冊聲明可供認購證券的數量不足以覆蓋可註冊證券的情況下，公司應在必要和可允許的範圍內修改初次註冊聲明或提交新的註冊聲明（以及其中的任何招股書或招股說明書，合稱爲「註冊聲明」），以儘快覆蓋所有這些可註冊證券，但在最遲提交期限之前。公司應盡商業上合理的努力，使此類修正和/或新註冊聲明在提交後儘快生效，但不得遲於（a）SEC通知公司將「審查」新的註冊聲明後的七十五（75）個日曆日內的初次提交日期，或者（b）在公司收到SEC口頭或書面通知之後的第五個（5）個工作日內，此通知較早，其中通知稱新的註冊聲明將不被「審查」或不會再接受進一步審查。新的註冊聲明公司應盡商業合理努力確保此類修正和/或新註冊聲明在提交後儘快生效，但在提交之日起不遲於（a）新註冊聲明初次提交日期的七十五（75）個日曆日，若SEC通知公司將「審查」新註冊聲明以及（b）公司口頭或書面接到SEC通知的第五（5）個工作日內之早者。 第2條（a） 和 第2條（b）將適用於新的註冊聲明，但受此處修改。

(d)            可容許的 延遲在任何十二（12）個月的期間內，公司最多隻能在不超過三十（30）連續天或總計不超過六十（60）天的情況下，可以延遲首次申報註冊文件或任何其他註冊文件的生效日期，或暫停使用任何註冊文件中包含的招股說明書，前提是董事會經過合理判斷，並根據法律顧問的建議，認爲此類延遲或暫停是必要的，以（A）延遲披露涉及公司的重要非公開信息，包括與公司尚未達成的重要交易相關的信息，這將要求公司在註冊文件中額外披露重要非公開信息，公司有保留爲機密的正當業務目的，並且在董事會合理決定（在法律顧問的建議下），如果不披露該信息可能會導致註冊文件不符合適用的披露要求；或者（B）修改或補充受影響的註冊文件或相關招股說明書，以使該註冊文件或招股說明書不包括重要事實的不實陳述或遺漏其中應該陳述的重要事實，或者使招股說明書的陳述在其製作時的情況下，不會誤導（稱爲“允許延遲”); 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；公司應當及時（a）書面通知每位投資者允許延遲的開始，但不得（未經投資者的書面同意）向投資者披露導致允許延遲的任何重要的非公開信息，（b）書面告知投資者在允許延遲結束之前停止適用註冊文件下的所有銷售，且（c）盡商業上的合理努力盡快終止允許的延遲。每位投資者可以發出書面通知（稱爲“退出通知向公司發出請求，要求不接收公司根據本 第2; 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。部分要求的通知，該投資者可以隨後書面撤銷任何此類選擇退出通知，該通知在收到後的五個工作日內生效。收到投資者的選擇退出通知後（除非後來撤銷），公司將不會向該投資者遞送任何根據本 第2(d)部分的通知，該投資者將不再享有與任何該等通知相關的權利。

(e)            規則415；削減如果SEC隨時認爲在任何登記聲明中的部分或全部可登記證券的發行不符合證券法第415條規定，不能延遲或連續進行發行(， 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。公司應盡商業上合理的努力，與SEC倡導登記所有可登記證券)，或要求命名任何投資者爲「承銷商」，公司 應(i)立即通知每位可登記證券持有人此事，並(ii)盡商業上合理的努力說服 SEC，認爲該登記聲明所設想的發行是有效的二級發行，而不是根據第415規則定義的「由發行人」發行，且沒有任何投資者是「承銷商。」 每位投資者 有權由其法律顧問自費對本 第2(e)部分審核，並監督根據本 第2(e)部分的條款涉及的任何登記或事項，包括就相關事項提交給SEC的任何書面提交進行評論。 如果 即使公司盡商業上合理的努力並遵守本 當SEC拒絕修改其立場時，公司應（i）從註冊聲明中刪除可註冊證券的部分，和/ 或（ii）同意SEC可能要求的爲確保公司符合規則415要求而進行的註冊和可註冊證券轉售受限的限制和限制（統稱，「SEC不修改其立場時，公司應（i）從註冊聲明中刪除可註冊證券的部分，和/ 或（ii）同意SEC可能要求的爲確保公司符合規則415要求而進行的可註冊證券註冊和轉售所需的限制和限制」SEC限制”); 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時；, 公司對於以下情況，不應承擔責任：根據第10（b）部分書面信息可靠地提供。即公司不得未經投資者事先書面同意在該註冊聲明中將任何投資者列爲「承銷商」在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時； 即，如果投資者不同意，則公司無需在任何涵蓋其可註冊證券的註冊聲明中包含該投資者的任何可註冊證券，直至SEC不再要求將該投資者列爲「承銷商」或該投資者書面同意被列爲「承銷商」爲止才有義務在其中包含投資者的可註冊證券。根據本「第2(e)節」對投資者實施的任何減少 第2(e) 節中規定的任何減少分配應在投資者之間按比例分配，並首先適用於SEC指示的不能納入或必須限制數量的任何投資者的可登記證券，然後再分配給所有其他投資者，除非SEC的限制另有要求或另有規定，或者投資者另有同意。

(f)             根據此處提交的每份註冊聲明應爲工表S-3（但如果公司當時不符合在工表S-3上註冊可轉讓證券的資格，則應根據本 第2(f)條）設立另一種表格進行註冊。如果工表S-3無法用於轉讓可註冊證券的註冊，則公司應（i）在其他適當的表格上註冊可註冊證券的轉讓，（ii）承諾在工表S-3可用時儘快註冊 在每種情況下，該B類股東和/或該B類股東的家庭成員需獨立控制在此類帳戶、計劃或信託中持有的B類普通股實時； 公司應保持註冊聲明的有效性直至工表S-3涵蓋的可註冊證券已被SEC宣告有效之時。

就註冊聲明和任何可註冊證券將要根據註冊的情況而言 第2節在初始註冊聲明或任何新的註冊聲明上，公司應盡商業上的合理努力按照擬定的處置方式進行註冊可登記證券，並據此公司應有以下義務：

(a)            通知書公司會及時通知投資者關於在SEC提交或生效的初次註冊聲明或任何新註冊聲明的後續修正（除了被引用的文件），或者其中是否已簽發收據，或者任何擬補充招股書的後續補充，以及SEC要求對註冊聲明、任何新註冊聲明或任何招股書進行修正或補充，或者額外信息的任何請求。

(b)            修訂公司將準備並向SEC提交任何修訂、生效後修訂或補充初步登記聲明、任何新的註冊聲明或相關招股說明書，並根據需要發帖維持該登記聲明的有效性，遵守證券法和交易法的規定，分配所有相關注冊證券，或者在投資者和公司的合理意見下，根據投資者對註冊證券進行的任何收購或銷售而必要或建議的任何情況下進行。

(c)            投資者 審查公司不會對註冊聲明、任何新的註冊聲明或任何擬議中的投資者、可登記證券或本次交易相關的招股書進行任何修正或補充，除非（A）投資者及其法律顧問在提交給SEC之前至少提前三（3）個工作日獲得通知並有機會對其進行審閱和評論，以及（B）公司已經合理考慮了投資者或其法律顧問提出的任何評論。

(d)            Copies Available. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement and its counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference therein), any prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement or any New Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished to the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment) and such other documents as such Investor may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Investor that are covered by such Registration Statement, in each case as soon as reasonably practicable upon such Investor’s request and in such quantities as such Investor may from time to time reasonably request; provided, however, that the Company shall not be required to furnish any document to such Investor to the extent such document is available on EDGAR.

(e)            Notification of Stop Orders; Material Changes. The Company shall use commercially reasonable efforts to (i) prevent the issuance of any stop order or other suspension of effectiveness and, (ii) if such order is issued, obtain the withdrawal of any such order as soon as practicable. The Company shall advise the Investors promptly (but in no event later than 24 hours) and shall confirm such advice in writing, in each case: (i) of the Company’s receipt of notice of any request by the SEC or any other federal or state governmental authority for amendment of or a supplement to the Registration Statement or any prospectus or for any additional information; (ii) of the Company’s receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness of the Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, or any New Registration Statement, or of the Company’s receipt of any notification of the suspension of qualification of the Registrable Securities for offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (iii) of the Company becoming aware of the happening of any event, which makes any statement of a material fact made in any Registration Statement or any prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement or any prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading, or of the necessity to amend any Registration Statement or any prospectus to comply with the Securities Act or any other law. The Company shall not be required to disclose to the Investors the substance of specific reasons of any of the events set forth in clauses (i) through (iii) of the immediately preceding sentence (each, a “Suspension Event”), but rather, shall only be required to disclose that the event has occurred; provided that the Company shall not provide any material non-public information to the Investors in such notice. If at any time the SEC, or any other federal or state governmental authority shall issue any stop order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, the Company shall use its commercially reasonable efforts to obtain the withdrawal of such order at the earliest practicable time. The Company shall furnish to any Investor upon request, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any other federal or state governmental authority to the Company or its representatives relating to the Initial Registration Statement, any New Registration Statement or any prospectus, or prospectus supplement as the case may be. In the event of a Suspension Event set forth in clause (iii) of the second sentence of this Section ‎3(e), the Company will use its commercially reasonable efforts to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under Registration Statements may resume.

(f)            Confirmation of Effectiveness. If requested by an Investor at any time in respect of any Registration Statement, the Company shall deliver to such Investor a written confirmation (email being sufficient) from Company’s counsel of whether or not the effectiveness of such Registration Statement has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not such Registration Statement is currently effective and available to the Company for sale of Registrable Securities.

(g)            Listing. The Company shall use commercially reasonable efforts to cause all Registrable Securities covered by a Registration Statement to be listed on the Nasdaq Global Market and/or any other National Exchange upon which the Registrable Securities are listed.

(h)            Compliance. The Company shall otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the SEC under the Securities Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final prospectus, including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under the Securities Act, promptly inform the Investor in writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof, the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and take such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement covering a period of at least twelve (12) months, beginning after the effective date of each Registration Statement, which earnings statement shall satisfy the provisions of Section 11(a) of the Securities Act, including Rule 158 promulgated thereunder (for the purpose of this Section ‎3(h), “Availability Date” means the forty-fifth (45^th) day following the end of the fourth (4^th) fiscal quarter that includes the effective date of such Registration Statement, except that, if such fourth (4^th) fiscal quarter is the last quarter of the Company’s fiscal year, “Availability Date” means the ninetieth (90^th) day after the end of such fourth (4^th) fiscal quarter).

(i)            Blue-Sky. The Company shall use commercially reasonable efforts to register or qualify or cooperate with any Investor and its counsel in connection with the registration or qualification of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested by such Investor; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section ‎3(i), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this Section ‎3(i), or (iii) file a general consent to service of process in any such jurisdiction.

(j)            Rule 144. With a view to making available to the Investors the benefits of Rule 144 (or its successor rule) and any other rule or regulation of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants and agrees to use commercially reasonable efforts to make and keep adequate current public information available, as those terms are understood and defined in Rule 144, until the date as all of the Initial Shares may be sold without restriction by the holders thereof pursuant to Rule 144 or any other rule of similar effect (without the requirement for the Company to be in compliance with any current public information requirements). In addition for so long as any Registrable Securities are outstanding, the Company covenants and agrees to use commercially reasonable efforts to (i) file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; (ii) furnish electronically to each Investor upon request, as long as such Investor owns any Registrable Securities, (A) a written statement by the Company that it has complied with the reporting requirements of the Exchange Act, (B) a copy of or electronic access to the Company’s most recent Annual Report on Form 10-K or Quarterly Report on Form 10-Q, and (C) such other information as may be reasonably requested in order to avail such Investor of any rule or regulation of the SEC that permits the selling of any such Registrable Securities without registration, and (iii) provide any legal opinions.

(k)            Cooperation. The Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule 144 free of any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of the Registrable Securities may reasonably request in accordance with the provisions of the Purchase Agreement, and the Company may satisfy its obligations hereunder without issuing physical stock certificates through the use of The Depository Trust Company’s Direct Registration System.

(l)             Removal of Restrictive Legends. Without limiting Section 5.5 of the Purchase Agreement, the Company shall use commercially reasonable efforts to cause the Company’s transfer agent to remove any restrictive legend from any Registrable Securities, as promptly as practicable following effectiveness of the applicable Registration Statement, without any request for removal being required from any holder of Registrable Securities.

(a)            Investor Information. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as Exhibit A or such other form of questionnaire or information required by the Company in connection with the registration of the Registrable Securities within three (3) Business Days of request by the Company and no later than the end of the third (3rd) Business Day following the date on which such Investor receives draft materials in accordance with Section ‎2(a).

(b)            Suspension of Sales. Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company of the existence of an Allowed Delay or Suspension Event, the Investor will promptly discontinue disposition of Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investor’s receipt of a notice from the Company confirming the resolution of such Allowed Delay or Suspension Event and that such dispositions may again be made.

(c)            Investor Cooperation. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the Company as reasonably requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement or New Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its Registrable Securities from such Registration Statement.

All Registration Expenses incurred in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities registered on behalf of an Investor shall be borne by such Investor.

(a)            To the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, each Person, if any, who controls each Investor, the shareholders, directors, officers, partners, employees, members, managers, agents, representatives and advisors of each Investor and each Person, if any, who controls any of the foregoing within the meaning of the Securities Act or the Exchange Act (each, an “Indemnified Person”), against any losses, obligation, claims, damages, liabilities, contingencies, judgments, fines, penalties, charges and costs (including, without limitation, court costs and costs of preparation), reasonable and documented attorneys’ fees, amounts paid in settlement or reasonable and documented expenses (collectively, “Indemnified Damages”) reasonably incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing by or before any court or governmental, administrative or other regulatory agency or body or the SEC, whether pending or threatened, whether or not an indemnified party is or may be a party thereto (“Claims”), to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement, or (ii) any violation or alleged violation by the Company or any of its Subsidiaries of the Securities Act, Exchange Act or any other state securities or other “blue sky” laws of any jurisdiction in which Registrable Securities are offered or any rule or regulation promulgated thereunder applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing clauses (i) and (ii) being, collectively, “Violations”). The Company shall reimburse each Indemnified Person promptly as such Indemnified Damages are incurred and are due and payable, for any reasonable out-of-pocket legal fees or other reasonable and documented expenses incurred by them in connection with investigating or defending any such Claim. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section ‎6(a): (A) shall not apply to a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information furnished in writing to the Company by the Investors or such Indemnified Person specifically for use in such Registration Statement and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection with the preparation of any Registration Statement; (B) with respect to any superseded prospectus, shall not inure to the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject thereof (or to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a Violation; (C) shall not be available to the extent such Claim is based on a failure of the Indemnified Person to deliver, or cause to be delivered, if required the prospectus to the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation of the sale of Registrable Securities; and (D) shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor pursuant to Section ‎8.

(b)            In connection with the Initial Registration Statement, any New Registration Statement or any prospectus, each Investor, severally and not jointly, agrees to indemnify, hold harmless and defend, the Company, each of its directors, and officers who signed the Initial Registration Statement or signs any New Registration Statement, and each Person, if any, who controls the Company within the meaning of the Securities Act or the Exchange Act (each, an “Indemnified Party”), against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from any untrue statement or alleged untrue statement or omission or alleged omission of any material fact contained in any Registration Statement or (ii) any violation or alleged violation by Investor of its obligations under this Agreement, in each case to the extent, and only to the extent, that such violation occurs in reliance upon and in conformity with information about such Investor furnished in writing by such Investor to the Company expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement. In no event shall the liability of an Investor be greater in amount than the dollar amount of the proceeds (net of all expense paid by such Investor in connection with any claim relating to this Section ‎6 and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received by such Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification obligation. Notwithstanding anything to the contrary contained herein, the indemnification agreement contained in this Section ‎6(b), shall not apply to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the such Investor, which consent shall not be unreasonably withheld, conditioned or delayed. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified Party and shall survive the transfer of the Registrable Securities by an Investor pursuant to Section ‎8.

(c)            Promptly after receipt by an Indemnified Person or Indemnified Party under this Section ‎6 of notice of the commencement of any action or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall, if a Claim in respect thereof is to be made against any indemnifying party under this Section ‎6, deliver to the indemnifying party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be, and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other expenses subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof; provided, however, that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented without conflict by one counsel) shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified Party or Indemnified Person which relates to such action or claim. The indemnifying party shall keep the Indemnified Party or Indemnified Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto. No indemnifying party shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however, that the indemnifying party shall not unreasonably withhold, delay or condition its consent. No indemnifying party shall, without the consent of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise unless such judgment or settlement (i) imposes no liability or obligation on, (ii) includes as an unconditional term thereof the giving of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii) does not include any admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person. Following indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this Section ‎6, except to the extent that the indemnifying party is prejudiced in its ability to defend such action.

(d)            The indemnification required by this Section ‎6 shall be made by periodic payments of the amount thereof during the course of the investigation or defense, as and when bills are received or Indemnified Damages are incurred. Any Person receiving a payment pursuant to this Section ‎6 which person is later determined to not be entitled to such payment shall return such payment (including reimbursement of expenses) to the person making it.

(e)            The indemnity agreements contained herein shall be in addition to (i) any cause of action or similar right of the Indemnified Party or Indemnified Person against the indemnifying party or others, and (ii) any liabilities the indemnifying party may be subject to pursuant to the law.

To the extent any indemnification by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect to any amounts for which it would otherwise be liable under Section ‎6 to the fullest extent permitted by law; provided, however, that: (i) no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation; and (ii) contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all expenses paid by such holder in connection with any claim relating to this Section ‎7 and the amount of any damages such holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by such seller from the sale of such Registrable Securities giving rise to such contribution obligation.

The Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) (voting together as a single class); provided, however, that in any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and the term “Registrable Securities” shall be deemed to include the securities received by the Investor in connection with such transaction unless such securities are otherwise freely tradable by the Investor after giving effect to such transaction, and the prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) shall not be required for such transaction. No Investor may assign its rights under this Agreement, other than to an affiliate of such Investor or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf of the Investor, without the prior written consent of the Company. The provisions of this Agreement shall be binding upon and inure to the benefit of the Investor and its successors and permitted assigns.

The provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a written instrument executed by (a) the Company and (b) the holders of a majority of the then outstanding Registrable Securities (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) (voting together as a single class), provided that (i) any party may give a waiver as to itself, (ii) any amendment, modification, supplement or waiver that disproportionately and adversely affects the rights and obligations of any Investor relative to the comparable rights and obligations of the other Investors shall require the prior written consent of such adversely affected Investor or each Investor, as applicable, and (iii) any amendments to Section ‎6 or to the definitions of “Filing Deadline,” “Effectiveness Deadline,” or “Registration Period” shall require the written consent of each Investor. Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights of one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors may be given by Investors holding a majority of the Registrable Securities (determined as if all of the Pre-Funded Warrants then outstanding have been exercised in full without regard to any limitations on the exercise of such Pre-Funded Warrants) to which such waiver or consent relates.

(a)            Notices. Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a) when delivered if personally delivered to the party for whom it is intended, (b) when delivered, if sent by electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next business day, provided no rejection or undeliverable notice is received, (c) three (3) days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written verification of receipt:

i.              If to the Company, addressed as follows:

GlycoMimetics, Inc.
9708 Medical Center Drive

Rockville, Maryland 20850

Attention: Christian Dinneen-Long

Email: cdinneen-long@glycomimetics.com

with a copy (which shall not constitute notice), prior to the Closing:

Sidley Austin, LLP
2850 Quarry Lake Drive, Suite 301
Baltimore, MD 21209
Attention: Asher Rubin
Email: arubin@sidley.com

with a copy (which shall not constitute notice), following the Closing:

Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111
Attention: Ryan Murr, Branden Berns; Chris Trester
Email: rmurr@gibsondunn.com, bberns@gibsondunn.com; ctrester@gibsondunn.com

ii.             If to any Investor, at its e-mail address or address set forth on Exhibit A to the Purchase Agreement or to such e-mail address, or address as subsequently modified by written notice given in accordance with this Section ‎10.

Any Person may change the address to which notices and communications to it are to be addressed by notification as provided for herein.

(b)            No Waiver. No failure or delay on the part of either party hereto in the exercise of any power, right or privilege under this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude any other or further exercise thereof or of any other right, power or privilege.

(c)            Governing Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury. The provisions of Section 8.5 of the Purchase Agreement are incorporated by reference herein mutatis mutandis.

(d)            Integration. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto) constitute the entire agreement between the parties hereto respecting the subject matter hereof and thereof and supersedes all prior agreements, negotiations, understandings, representations and statements respecting the subject matter hereof and thereof, whether written or oral.

(e)            Headings. The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation of, this Agreement.

(f)             Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not a facsimile or pdf (or other electronic reproduction of a) signature.

(g)            Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

(h)            Contract Interpretation. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

(i)             No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as expressly provided in this Agreement. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.

(j)             Severability. If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding upon the parties hereto.

(k)            Non-Recourse. Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents or instruments delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.

(l)             Specific Performance. In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement, each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunction or equitable relief as may be granted by a court of competent jurisdiction.

(m)           Cumulative Remedies. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.

[Signature Page to Registration Rights Agreement]

IN WITNESS WHEREOF, the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.

[Signature Page to Registration Rights Agreement]

Exhibit A

Investor Questionnaire

The undersigned hereby provides the following information to the Company and represents and warrants that such information is accurate:

QUESTIONNAIRE

Yes ¨      No ¨

Yes ¨      No ¨

Yes ¨      No ¨

Yes ¨      No ¨

Except as set forth below in this Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable pursuant to the Purchase Agreement.

The undersigned agrees to promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.

By signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related prospectus and any amendments or supplements thereto.

IN WITNESS WHEREOF the undersigned, by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized agent.

PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND EXECUTED QUESTIONNAIRE TO: